Convalescent plasma as a potential therapy for COVID-19

Chen, Long; Xiong, Jing; Bao, Lei; Shi, Yuan

doi:10.1016/s1473-3099(20)30141-9

Cited by 959 publications

(955 citation statements)

References 12 publications

Supporting

Mentioning

912

Contrasting

Unclassified

Order By: Relevance

“…CPT is an effective therapy choice, and has been successfully applied to the treatment of SARS and H1N1 influenza. 27 Before conducting CPT, pharmacists should assist clinicians in assessing patients' indications of CPT, combining with allergy history, contraindications of plasma transfusion, and individual clinical conditions. Also, the infusion dose should be formulated based on patients' weight and clinical condition, usually ranging from 200 ml to 500 mL (4-5 mL/kg).…”

Section: Monitoring and Management Of Convalescent Plasma Therapy (Cpt)mentioning

confidence: 99%

Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience

Song

Zheng

et al. 2021

Research in Social and Administrative Pharmacy

118

120

View full text Add to dashboard Cite

A B S T R A C TObjective: To discuss hospital pharmacists' role in providing pharmaceutical care for hospitalized patients with COVID-19 to promote patient care and management during the pandemic. Method: Based on the method of evidence-based pharmacy, clinical evidence of therapeutical drugs for COVID-19 were retrieved and summarized. Based on clinical experience Chinese hospital pharmacists gained from providing pharmaceutical care services during COVID-19 pandemic, taking COVID-19 hospitalized patients' needs into consideration, the methods and strategies hospital pharmacists shall use to provide pharmaceutical care were analyzed and summarized. Results: Hospital pharmacists shall support pharmaceutical care services by participating in making evidence-based decisions for medication, monitoring and evaluation of medication safety and efficacy, providing strengthened care for special population and patients with combined underlying diseases, monitoring and management of convalescent plasma therapy, providing emotional counselling and psychological support, and providing scientific information about COVID-19 vaccines. Conclusion: The need of pharmaceutical care services in COVID-19 hospitalized patients during this pandemic was quite distinguished from the past. Hospital pharmacists shall join the collaborative multidisciplinary team to improve COVID-19 patients' outcome and reduce mortality, and to facilitate the pandemic control.

show abstract

Section: Monitoring and Management Of Convalescent Plasma Therapy (Cpt)mentioning

confidence: 99%

Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience

Song

Zheng

et al. 2021

Research in Social and Administrative Pharmacy

118

120

View full text Add to dashboard Cite

show abstract

“…The FDA has approved the using of blood plasma from patients who have recovered from COVID-19 with a high neutralizing antibody titer and they may be a valuable donor source of convalescent plasma (CP) [70]. CP is a classic adaptive immunotherapy, has been applied to the prevention and treatment of many infectious diseases for more than one century.…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status

El-Aziz

Stockand

2020

Infection, Genetics and Evolution

300

283

View full text Add to dashboard Cite

show abstract

“…While waiting for a specific vaccine, a similar approach to that used for immunotherapies in the treatment of cancer and serious viral respiratory infections could represent an option for the prevention and treatment of SARS-CoV-2. For instance, a solution could be represented by the passive immunization, which is the administration of serum containing specific antibodies taken from patients from SARS-CoV-2 [12]. Unlike active immunization, this approach does not require the activation of the recipient's immune responses and generates an immediate immune response.…”

Section: Mersmentioning

confidence: 99%

SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment

Mauro

Scavone

Rafaniello

et al. 2020

International Immunopharmacology

View full text Add to dashboard Cite

The new coronavirus outbreak is an ongoing pandemic that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The new coronavirus SARS-Cov-2 belongs to the subfamily of β−coronaviruses and shares 79.5% of the genetic sequence of SARS-CoV, the causative agent of the epidemic that started in 2002 and ended in 2004.Considering the clinical impact of the new outbreak, it is highly important to study the potential responses of the human immune system during the SARS-CoV-2 infection as well as the role of virus-specific T cells and by B-lymphocytes. Moreover, specific data on the production of IgG and IgM is crucial to allow the rapid identification of the infection. In this paper we also described the importance of sensitive and specific rapid test for SARS-CoV-2. Indeed, this test represents an important immunological tool aimed at identifying the precise phase of the infection in order to undertake a more appropriate pharmacological treatment. Lastly, we provided an overview of pharmacological treatments aimed to reduce inflammatory processes underlying the infection and the need for the discovery of a new vaccine against SARS-CoV-2.

show abstract

Convalescent plasma as a potential therapy for COVID-19

Cited by 959 publications

References 12 publications

Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience

Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status

SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment

Contact Info

Product

Resources

About